Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/33809
Title: Impact of the COVID-19 Pandemic on Healthcare Access and Diagnosis of Pulmonary Arterial Hypertension Among Patients with Systemic Sclerosis.
Austin Authors: Callisto, Alicia;Hansen, Dylan;Walker, Jenny;Ngian, Gene Siew;Apostolopoulos, Diane;Liew, David F L ;Chand, Vibhasha;Hill, Catherine L;Griggs, Kim;Calderone, Alicia;Nikpour, Mandana;Sahhar, Joanne;Stevens, Wendy;Proudman, Susanna
Affiliation: Immunology Unit, Royal Adelaide Hospital, Adelaide, 5000, Australia.
St. Vincent's Hospital, 41 Victoria Pde, Fitzroy, Melbourne, Victoria, 3065, Australia.
Rheumatology Unit, Flinders Medical Centre, Adelaide, South Australia, Australia.
Department of Medicine, Monash University, Clayton.
Monash Health, Melbourne, Victoria, Australia.
Rheumatology
School of Public Health and Preventative Medicine, Monash University, Melbourne, Australia.
Rheumatology Unit, The Queen Elizabeth Hospital, Woodville, South Australia, Australia.
Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, 5000, Australia.
Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.
Department of Medicine, Monash University, Clayton.;Monash Health, Melbourne, Victoria, Australia.
Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.
Issue Date: Jan-2024
Date: 2023
Publication information: Arthritis Care & Research 2024-01; 76(1)
Abstract: Regular clinical assessment for complications of systemic sclerosis (SSc) such as pulmonary arterial hypertension (PAH), is essential for early institution of therapy and improved outcomes. The objective of this study was to determine the impact of COVID-19 pandemic-related restrictions on healthcare access of SSc patients, including screening for PAH. South Australian and Victorian patients enrolled in the Australian Scleroderma Cohort Study were surveyed about their perceptions of the impact of the pandemic on mental well-being, access to medications, investigations and management of SSc. Frequency of annual rheumatology assessments, pulmonary function tests (PFT) and transthoracic echocardiography (TTE) to screen for PAH were compared with pre-pandemic rates. 312/810 SSc patients responded (38.5% response). 273 (87.5%) were female, median age 64.7 years, 77.2% had limited disease, median illness duration 15.6 years, 15.7% were immunosuppressed, 32.1% had interstitial lung disease and 6.4% had PAH. 65.7% of consultations were by telehealth, of which 81.2% were by telephone. Compared with respondents in SA (n=109), VIC respondents (n=203) experiencing prolonged lockdown, reported reduced access to their rheumatologist (49.3% vs 27.9%, p=0.004), greater use of consultation by video (17.3% vs 2.1%, p=0.008), greater healthcare disruption (49.0% vs 23.2%, p<0.001) and worse mental health (p=0.002). Respondents reported reduced access to PFT and TTE (31.7% and 22.5% respectively). Annual visits, PFT, TTE and new diagnoses of PAH were reduced in 2020-2022 compared with 2011-2019. COVID-19 pandemic-related disruption to healthcare for SSc patients was associated with worse mental health and reduced screening and diagnosis of PAH which may impact long-term outcomes. This article is protected by copyright. All rights reserved.
URI: https://ahro.austin.org.au/austinjspui/handle/1/33809
DOI: 10.1002/acr.25239
ORCID: 0000-0002-3639-3040
0000-0003-1078-6732
0000-0001-8451-8883
0000-0001-8289-4922
0000-0001-8925-6771
0000-0002-3046-9884
Journal: Arthritis Care & Research
PubMed URL: 37728139
ISSN: 2151-4658
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

28
checked on Oct 5, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.